DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”), is pleased to announce the launch of its first mobile cannabis store, licensed by the Liquor Gaming and Cannabis Authority of Manitoba (“LGCA”) to sell cannabis on-site at the 2022 Dauphin Countryfest and the 2022 Rock the Fields Minnedosa music festivals. Delta 9 is working with the LGCA to ensure the mobile unit meets the same safety and security requirements as Delta 9’s permanent retail store network. The Company believes this will be Canada’s first licensed mobile retail store to sell cannabis at music festivals.

Sproutly Canada, Inc. (SRUTF) (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) ("Sproutly" or the "Company"), announces that it is expanding its commercial relationship with Kingston Cannabis Inc. ("KCI"), a Health Canada Licensed processor.

 springbig, a leading provider of SaaS-based marketing solutions, consumer mobile app experiences, and omnichannel loyalty programs to the cannabis industry, today announced a new integration with Greenline POS, one of Canada's largest fully-compliant cannabis retail point-of-sale (POS) platforms. This integration provides springbig with real-time consumer and retail insights at checkout and will allow retailers using Greenline's services to seamlessly access springbig's customer loyalty features.

IM Cannabis Corp. (the “Company” or “IM Cannabis“) (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, today announced new strategic imperatives designed to enhance organizational efficiency and reduce operating costs while further responding to the increased demand for premium, indoor-grown Canadian cannabis from Israeli consumers. As part of these changes, Focus Medical Herbs Ltd. (“Focus Medical”) has decided to close the Sde Avraham cultivation farm in Israel that it owns and operates. Focus Medical has an exclusive commercial agreement with IM Cannabis to distribute its production under the IMC brand.

The all-in-one weed growing device is no more.

Grobo is dead.

According to several reports and a Linkedin post from Bjorn Dawson, the company’s CEO and co-founder, Waterloo-based cannabis growing device startup Grobo has gone out of business after declaring bankruptcy in early January.

The Business Development Bank of Canada now owns the company’s assets and it’s unclear what the future holds for current Grobo users.

As of right now, the servers powering the company’s automated growth system remain online, however. That said, there are reports of Grobo Grow Box 2nd-generation buyers not receiving their devices and being forced to perform chargebacks on their credit cards. Grobo sold its grow devices in the U.S. and Canada.

WebJoint, a California-based all-in-one delivery software provider, has announced a partnership and integration with Cova, a Denver, CO and Vancouver, BC, Canada-based award-winning point-of-sale and inventory management platform used by over 2,000 cannabis retailers in the U.S. and Canada.

In this partnership, WebJoint’s cannabis delivery software will be available to Cova’s customer network of retail dispensaries that want to implement delivery. Previously, WebJoint has launched similar integrations with other industry-related tech providers.

The leader in the cannabis delivery industry looks to transform the industry with its new cryptocurrency.

Greenlyght Coin, a groundbreaking blockchain technology on the binance smartchain that utilizes real-world utilities to bridge the gap between cryptocurrency and cannabis, has officially launched one of the most successful token launches of 2022. By merging two of the fastest-growing industries in the world, Greenlyght's software (sometimes referred to as "The Company") has grown into a leader in the cannabis delivery space. 

Cannabotech’s idea is not to replace existing cancer treatments but to enable a patient to have fewer treatments with the same benefit.

New Health Canada program expands physicians’ ability to prescribe the illegal substance

Vancouver drug-research companies are seeking cheaper ways to produce psychedelic mushrooms, or the active ingredient psilocybin, to cater to new demand. 

One longer-term trend has been for pharmaceutical companies to invest in creating psilocybin-based drugs that treat depression, addictions, post-traumatic stress disorder and other conditions.

Health Canada in January launched what it calls a “special access program” that allows physicians to request that government grant patients access to psilocybin, which is otherwise illegal to possess and produce.